Novo Nordisk A/S (NYSE:NVO) Announces Earnings Results

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Wednesday. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03, Zacks reports. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. Novo Nordisk A/S updated its FY 2025 guidance to EPS.

Novo Nordisk A/S Stock Up 4.7 %

Shares of NYSE NVO traded up $3.91 during midday trading on Wednesday, hitting $86.53. The company’s stock had a trading volume of 8,258,214 shares, compared to its average volume of 9,251,293. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The business’s fifty day simple moving average is $92.65 and its two-hundred day simple moving average is $112.19. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $388.28 billion, a price-to-earnings ratio of 28.00, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent analyst reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.